Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00411398 · ClinicalTrials.gov registry record · Phase 3
A 10 Week Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Memantine(Namenda) as Augmentation Therapy in Patients With Generalized Anxiety Disorder
A Phase 3 study, sponsored by State University of New York - Upstate Medical University.
- Completed
- Registry status
- Phase 3
- Development phase
- 15
- Enrollment target
NCT00411398: Completed Phase 3 study, sponsored by State University of New York - Upstate Medical University.
NCT00411398 is a Phase 3 study that has completed, run by State University of New York - Upstate Medical University. The registered enrollment target is 15 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00411398, a Phase 3 study, has completed, sponsored by State University of New York - Upstate Medical University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 15 participants
- Enrollment target
Study Summary
This study is being conducted to evaluate the safety and effectiveness of memantine Add-On treatment of patients who are currently taking an SNRI or SSRI and who remain anxious and symptomatic despite treatment. Secondary objectives of this study are: •-to evaluate if there is an improvement in disability levels following memantine dosing -to evaluate if there is an improvement in sleep quality following memantine dosing
Primary Outcome
Standard Clinical Depression Rating Scale. Clinician administered. Scale units are points/numbers. Possible range is 0 to 44 with the latter signifying more severe anxiety
Interventions
- DRUG Namenda/Memantine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2006-12 |
| Est. Completion | 2010-05 |
| Phase | Phase 3 |
What the finished NCT00411398 record still lists
NCT00411398 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Namenda/Memantine is the first listed.
NCT00411398 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00411398 about?
NCT00411398 is a clinical study titled "A 10 Week Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Memantine(Namenda) as Augmentation Therapy in Patients With Generalized Anxiety Disorder". This study is being conducted to evaluate the safety and effectiveness of memantine Add-On treatment of patients who are currently taking an SNRI or SSRI and who remain anxious and symptomatic despite treatment. Secondary objectives of this study are: •-to evaluate if there is an improvement in di...
What is the current status of trial NCT00411398?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 15 participants. The study started on 2006-12. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00411398?
The interventions under investigation include: Namenda/Memantine (DRUG).
Who is sponsoring clinical trial NCT00411398?
This trial is sponsored by State University of New York - Upstate Medical University, which has 113 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00411398's enrollment target sits among peer trials
15 1977th of 2000 higher than 18 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia